CTOs on the Move

Pathology, Inc.

www.pathologyinc.com

 
Pathology Inc. is a 30 man pathology group headquartered in suburban Los Angeles, California offering multi-specialty pathology services for primary care and specialty physicians. The group also practices at 12 area hospitals.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Pacific Coast Laboratories Inc

Pacific Coast Laboratories Inc is a San Leandro, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bronx AIDS Services

Bronx AIDS Services (BAS), an AIDS service organization, helps more than 25,000 Bronx residents each year with an array of free services designed to meet the needs of this ethnically and culturally diverse community. Our services include: Extensive

Black and Black Surgical

Black and Black Surgical is a Tucker, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

University of North Carolina, School of Medicine

Our mission is to improve the health and wellbeing of North Carolinians and others whom we serve. We accomplish this by providing leadership and excellence in the interrelated areas of patient care, education, and research. We strive to promote faculty, staff and learner development in a diverse, respectful environment where our colleagues demonstrate professionalism, enhance learning, and create personal and professional sustainability. We optimize our partnership with the UNC Health Care System through close collaboration and a commitment to service.

Ampio Pharmaceuticals

Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending.  Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™.  The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.  Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema.  Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.